Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
In the provided medical discussion, Dr. Noa Biran, an expert in relapsed/refractory multiple myeloma (RRMM), highlighted the complexity of treatment decisions. She emphasized the vast array of available therapies and the challenge of managing relapses after each treatment line. Factors like patient health, previous responses, and disease biology dictate treatment choices. Despite advancements, resistance remains a hurdle, leading to therapy changes and eventual relapse. Dr. Biran stressed the persistent need for novel therapies and combinations to improve patient outcomes. She touched upon recent drug approvals like talquetamab, elranatamab, and teclistamab, and highlighted trials assessing their safety and efficacy. The talk concluded with the ongoing quest to optimize sequencing and combinations, aiming to address unmet needs and enhance the management of RRMM in both transplant-eligible and ineligible patients.
Video synopsis is AI-generated and reviewed by Cancer Network editorial staff.
